Valion Bio sells Series C preferred shares, warrants in $4.72 million private placement
Bitget2026/10/27 10:09- Valion Bio agreed October 26, 2026, to privately place 4,717 Series C Non-Voting Convertible Preferred Shares for $4.72 million.
- The purchase price comprises $1.5 million in cash and $3.22 million retained by purchasers to satisfy overdue cash true-up payments.
- Series C purchasers also receive warrants to buy 2,524,343 common shares at an initial exercise price of $1.0092 per share.
- A separate private placement to 3i covers 50 Series B Non-Voting Convertible Preferred Shares for $50,000.
- The Series B placement includes warrants to purchase 1,539 common shares at an initial exercise price of $1.0092 per share.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ekopak Expands Wastewater Treatment Plant at Mark Anthony Brewing
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
Crypto prices
More
